Company Description
Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments in the United States.
It develops software application NOCISCAN that involves NOCISCAN MRS Exam Protocol which extends the time of a standard lumbar MRI exam by an average of about 30 minutes for 5 lumbar discs; Data Transfer to transfer data from MR scanners to externally hosted cloud post-processors; and The NOCISCAN Post-Processor Suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.
The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021.
Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
| Country | United States |
| Founded | 2008 |
| IPO Date | Apr 22, 2022 |
| Industry | Health Information Services |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Brent Ness |
Contact Details
Address: 8181 Arista Place, Suite 100 Broomfield, Colorado 80021 United States | |
| Phone | 833 275 2266 |
| Website | aclarion.com |
Stock Details
| Ticker Symbol | ACON |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.35 |
| CIK Code | 0001635077 |
| CUSIP Number | 655187102 |
| ISIN Number | US6551872012 |
| Employer ID | 47-3324725 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Brent Ness | Chief Executive Officer, President and Director |
| Dr. Jeffrey John Thramann M.D. | Executive Chairman |
| John Lorbiecki | Chief Financial Officer |
| Ryan Bond | Chief Strategy Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 11, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Dec 2, 2024 | DEF 14A | Other definitive proxy statements |
| Nov 27, 2024 | 8-K | Current Report |
| Nov 22, 2024 | PRE 14A | Other preliminary proxy statements |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | EFFECT | Notice of Effectiveness |
| Nov 8, 2024 | 424B3 | Prospectus |
| Nov 7, 2024 | UPLOAD | Filing |
| Nov 5, 2024 | 424B3 | Prospectus |